The protein, the receptor, the hormone: Akkermansia and GLP-1

You have heard of GLP-1 even if you do not know the acronym. It is the hormone that drugs like semaglutide work through — the molecule at the centre of the largest conversation in metabolic medicine right now. What fewer people know is that your own gut makes GLP-1 naturally, and that Akkermansia muciniphila is one of the bacteria connected to that process. In 2021, scientists worked out exactly how.

What GLP-1 actually does

GLP-1 — glucagon-like peptide-1 — is released by specialised cells in your intestinal wall called L-cells. It helps regulate blood sugar after meals, slows stomach emptying, and signals fullness to the brain. It is a normal, endogenous part of how your body handles food. The blockbuster drugs are essentially powerful, long-lasting mimics of this natural hormone.

The 2021 discovery: a bacterial protein that triggers GLP-1

Here is where it gets remarkable. In 2021, Hyun Sik Yoon and colleagues went looking through the proteins that Akkermansia secretes, searching for one that might stimulate GLP-1 release. They found it: a single protein they named P9 (Yoon et al., 2021).

The mechanism is specific, not vague:

• Akkermansia secretes P9.
• P9 binds a receptor called ICAM-2 on the surface of intestinal L-cells.
• That binding triggers the L-cells to release GLP-1.

And when they gave P9 alone — no bacterium at all — to obese mice, it increased circulating GLP-1, improved glucose tolerance, raised energy expenditure, and reduced weight gain. Remove the ICAM-2 receptor, and the effect disappeared. That is how you know a mechanism is real: a specific protein, a specific receptor, a specific hormone, and a clean off-switch.

This finding appeared in Nature Microbiology, a top-tier journal. So the shorthand — "Akkermansia is the bug behind the GLP-1 conversation" — is not marketing language. It is a published, mechanistic result.

An important dose of honesty

P9's effect is on your gut's own GLP-1 release — it nudges a natural process, not in the same magnitude class as pharmaceutical GLP-1 receptor agonists, and Vekovia is not a weight-loss drug or an alternative to one. Most of this work is also in animals; the human evidence (Depommier et al., 2019) is still early. We describe rather than promise.

What we can fairly say is that Akkermansia sits at a genuinely interesting intersection of the gut, metabolism, and appetite that scientists are actively studying. That is why it anchors Vekovia · Bilberry, our metabolic-leaning pairing.

Why the berries belong here too

The mechanism also explains why we pair the bacterium with berries rather than selling it alone. The logic runs: berry polyphenols are linked in research to higher Akkermansia abundance (Henning et al., 2017 for pomegranate; similar findings for other berry polyphenols) → more Akkermansia → more of the surface proteins and secreted factors, like Amuc_1100 (Plovier et al., 2017) and P9, that the research connects to metabolic effects.

We feed the bacterium, in other words — and the science of why is unusually well mapped for a food supplement.